Viking Therapeutics, Inc. (VKTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $29.42: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum.
Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for obesity in Phase 3 VANQUISH trials (SC) and Phase 3 initiation planned Q3 2026 (oral), plus VK2809 for NASH/MASH. No products approved; relies on Ligand-licensed... Read more
Sell if holding. Engine safety override at $29.42: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Score 4.4/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
About Viking Therapeutics, Inc.
About Viking Therapeutics, Inc.
Viking Therapeutics enrolled the VANQUISH-1 Phase 3 obesity study in November 2025 and initiated the companion VANQUISH-2 study — both evaluating subcutaneous VK2735, a GLP-1/GIP dual agonist that produced up to 14.7% body weight reduction in the Phase 2 VENTURE trial. The oral tablet formulation of VK2735 achieved up to 12.2% body weight loss in Phase 2 results announced August 2025. With an accumulated deficit of $847.5 million at December 31, 2025, Viking held $705.7 million in cash, cash equivalents, and investments.
Viking Therapeutics generates no commercial revenue and funds operations through equity offerings; the March 2024 underwritten offering raised $597.1 million in net proceeds at $85.00 per share for 7,441,650 shares. The pipeline spans VK2735 subcutaneous (Phase 3, VANQUISH program, 78-week trials), VK2735 oral (Phase 2 complete; Phase 3 initiation targeted Q3 2026), VK2809 (Phase 2b positive MASH/NASH data, including up to 75% NASH resolution at 52 weeks versus 29% for placebo), and VK0214 (Phase 1b complete in X-linked adrenoleukodystrophy). In March 2025, the company secured manufacturing agreements with Corden Pharma Colorado covering API and final finished product for VK2735 — including dedicated capacity for multiple metric tons of API annually, 100 million autoinjectors per year, and over one billion oral tablets per year. Technology underlying VK2809, VK0214, VK5211, and VK0612 is licensed from Ligand Pharmaceuticals under the Master License Agreement, which grants Ligand termination rights in the event of Viking's insolvency or failure to cure a material obligation default.
Show full overview
Viking Therapeutics' near-term valuation is anchored to the VANQUISH Phase 3 readout for subcutaneous VK2735 — the only program at the Phase 3 stage in the pipeline at December 31, 2025. If the VANQUISH studies fail to replicate Phase 2 efficacy or reveal unexpected safety signals, the company's ability to raise the additional capital it acknowledges needing could be significantly impaired, given that it has never generated revenue and carried an $847.5 million accumulated deficit. Separately, the Ligand Master License Agreement covers VK2809, VK0214, VK5211, and VK0612; its termination would remove most of the secondary pipeline simultaneously.
See also: Healthcare · Biotechnology
From Viking Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-06-15Recent Developments — Viking Therapeutics, Inc.
Latest news
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga Jun 5, 2026 neutral
- NEWS Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89 — benzinga May 28, 2026 positive
- NEWS Viking Therapeutics Presents Additional Data From Phase 2 VENTURE-Oral Dosing Trial Evaluating Oral Tablet Formulation O — benzinga May 12, 2026 positive
- NEWS Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port — benzinga May 4, 2026 neutral
- NEWS Cantor Fitzgerald Maintains Overweight on Viking Therapeutics, Lowers Price Target to $100 — benzinga Apr 30, 2026 positive
Generated 2026-06-17T08:41:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $29.42: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Prior stop was $27.35. Score 4.4/10, moderate confidence.
Take-profit target: $32.50 (+10.5% upside). Prior stop was $27.35. Stop-loss: $27.35.
DATA_ISSUE: analyst_target_implausible (raw $92.58 vs price $29.41 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (1.5 < 4.0).
Viking Therapeutics, Inc. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 5.0/10. Verdict: Sell.
26 analysts cover VKTX with a consensus score of 4.2/5. Average price target: $93.
What does Viking Therapeutics, Inc. do?Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for...
Viking Therapeutics is a clinical-stage biopharmaceutical company developing VK2735 (GLP-1/GIP dual agonist) for obesity in Phase 3 VANQUISH trials (SC) and Phase 3 initiation planned Q3 2026 (oral), plus VK2809 for NASH/MASH. No products approved; relies on Ligand-licensed technology and CordenPharma for VK2735 API and fill/finish manufacturing under multi-year agreements.